Persistent pain, sensory disturbances and functional impairment after adjuvant chemotherapy for breast cancer: Cyclophosphamide, epirubicin and fluorouracil compared with docetaxel + epirubicin and cyclophosphamide

Author： Andersen Kenneth Geving   Jensen Maj-Britt   Kehlet Henrik   Gärtner Rune   Eckhoff Lise   Kroman Niels  

Publisher： Informa Healthcare

ISSN： 0284-186X

Source： Acta Oncologica, Vol.51, Iss.8, 2012-11, pp. : 1036-1044

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer

By Abe Hajime  

International Journal of Clinical Oncology, Vol. 18, Iss. 3, 2013-06 ,pp. : 487-491

Springer Publishing Company

Access to resources Recommend Favorite

Adjuvant fluorouracil, epirubicin and cyclophosphamide in early breast cancer: Is it cost-effective?

By Norum Jan   Holtmon Mari  

Acta Oncologica, Vol. 44, Iss. 7, 2005-10 ,pp. : 735-741

Informa Healthcare

Access to resources Recommend Favorite

Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil–epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy

By Ohno S.   Chow L.   Sato N.   Masuda N.   Sasano H.   Takahashi F.   Bando H.   Iwata H.   Morimoto T.   Kamigaki S.   Nakayama T.   Nakamura S.   Kuroi K.   Aogi K.   Kashiwaba M.   Yamashita H.   Hisamatsu K.   Ito Y.   Yamamoto Y.   Ueno T.   Fakhrejahani E.   Yoshida N.   Toi M.  

Breast Cancer Research and Treatment, Vol. 142, Iss. 1, 2013-11 ,pp. : 69-80

Springer Publishing Company

Access to resources Recommend Favorite

Cyclophosphamide, epirubicin and fluorouracil chemotherapy-induced alteration of haemostasis markers in breast cancer patients

By                

Molecular and Clinical Oncology, Vol. 3, Iss. 5, 2015-01 ,pp. : 1088-1092

Science Publishers

Access to resources Recommend Favorite

Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1–3 node-positive rapidly proliferating breast cancer

By Amadori Dino   Silvestrini Rosella   Lena Mario   Boccardo Francesco   Rocca Andrea   Scarpi Emanuela   Schittulli Francesco   Brandi Mario   Maltoni Roberta   Serra Patrizia   Ponzone Riccardo   Biglia Nicoletta   Gianni Lorenzo   Tienghi Amelia   Valerio Maria   Bonginelli Paola   Amaducci Laura   Faedi Marina   Baldini Editta   Paradiso Angelo  

Breast Cancer Research and Treatment, Vol. 125, Iss. 3, 2011-02 ,pp. : 775-784

Springer Publishing Company

Access to resources Recommend Favorite